| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | JQ-1:MK-0752 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |